Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo Controlled Study to Estimate the Effect Size of Glutamine as a Supplement to Prevent Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma Patients

NCT01783522 is registered in ClinicalTrials.gov with Beth Faiman as lead sponsor.

NCT NCT01783522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01783522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo Controlled Study to Estimate the Effect Size of Glutamine as a Supplement to Prevent Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma Patients
Lead sponsor
Beth Faiman
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2013
Completion date
November 30, 2013
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapeutic agent toxicity, multiple myeloma, peripheral neuropathy